Understanding HER2 Negative Breast Cancer: What It Means for Diagnosis and Treatment

Receiving a breast cancer diagnosis involves understanding various factors that help guide treatment decisions. One critical piece of information is the tumor's HER2 status. If you've encountered the term "HER2 negative," it refers to a specific characteristic of breast cancer cells. This article aims to clarify what HER2 negative means, how it's determined, and its general implications for treatment approaches, providing valuable context for those navigating this diagnosis.

What Does "HER2 Negative" Actually Mean?

HER2 stands for Human Epidermal growth factor Receptor 2. It's a gene that makes HER2 proteins, which are receptors found on the surface of all breast cells. These receptors play a role in cell growth, division, and repair. In some breast cancers, there are too many copies of the HER2 gene, leading to an overproduction of HER2 proteins. This is known as HER2 positive breast cancer, and these extra proteins act like "on" switches, telling the cancer cells to grow and divide rapidly.

When a breast cancer is described as "HER2 negative," it means that the cancer cells do not have an excess of HER2 proteins on their surface. In other words, the HER2 gene is not amplified, and the protein level is normal or low. This distinction is crucial because it influences which targeted therapies will be effective.

How HER2 Status is Determined

Determining a tumor's HER2 status is a standard part of breast cancer diagnosis. This information is typically obtained from a biopsy of the tumor tissue or from surgical samples. Two primary tests are used:

• Immunohistochemistry (IHC): This test measures the amount of HER2 protein on the surface of the cancer cells. The results are scored from 0 to 3+. A score of 0 or 1+ usually indicates HER2 negative. A score of 3+ indicates HER2 positive. A score of 2+ is considered "equivocal" or "borderline," meaning further testing is needed.
• Fluorescence In Situ Hybridization (FISH) or Chromogenic In Situ Hybridization (CISH): If the IHC test is equivocal (2+), a FISH or CISH test is performed. These tests look directly for extra copies of the HER2 gene within the cancer cells. If no extra copies of the gene are found, the tumor is confirmed as HER2 negative.

Pathologists analyze these samples to provide a definitive HER2 status, which is then used by oncologists to tailor treatment plans.

HER2 Negative vs. HER2 Positive: Key Differences

The main difference between HER2 negative and HER2 positive breast cancer lies in their biological characteristics and, consequently, their treatment options. HER2 positive cancers are often more aggressive but respond well to specific anti-HER2 targeted therapies, such as trastuzumab (Herceptin) or pertuzumab (Perjeta), which block the HER2 protein's growth signals. For HER2 negative cancers, these targeted therapies are not effective because there isn't an overexpression of the HER2 protein to target.

Therefore, knowing the HER2 status helps oncologists avoid ineffective treatments and focus on therapies that are more likely to work for a specific tumor type.

Treatment Approaches for HER2 Negative Breast Cancer

Since HER2 negative breast cancers do not respond to anti-HER2 targeted therapies, treatment strategies focus on other characteristics of the cancer cells. The exact treatment plan will depend on several factors, including the tumor's hormone receptor status (estrogen receptor and progesterone receptor), tumor size, lymph node involvement, and the patient's overall health. Common treatment approaches may include:

• Surgery: To remove the tumor (lumpectomy or mastectomy).
• Radiation Therapy: Often used after surgery to destroy any remaining cancer cells in the breast or chest area.
• Chemotherapy: Systemic treatment that uses drugs to kill cancer cells throughout the body. This is a common treatment for many HER2 negative cancers, especially those that are more aggressive or have spread.
• Hormone Therapy: If the cancer is also hormone receptor positive (meaning it grows in response to estrogen or progesterone), hormone therapy drugs can block these hormones or lower their levels, thereby slowing or stopping cancer growth.
• Immunotherapy: In some specific subsets of HER2 negative breast cancer, particularly triple-negative breast cancer, immunotherapy may be an option.

Triple-Negative Breast Cancer: A Specific Type of HER2 Negative

It's important to mention a specific subtype of HER2 negative breast cancer known as Triple-Negative Breast Cancer (TNBC). TNBC is defined by being negative for HER2, estrogen receptors (ER), and progesterone receptors (PR). This means it does not respond to hormone therapy or HER2-targeted therapies. TNBC is often more aggressive and has different treatment considerations, primarily relying on chemotherapy and, increasingly, immunotherapy or PARP inhibitors for specific genetic mutations.

Living with HER2 Negative Breast Cancer

A HER2 negative diagnosis provides crucial information for personalizing treatment. While it means certain targeted therapies aren't applicable, it opens the door to other effective treatments tailored to the tumor's specific biology. Patients should work closely with their oncology team to understand their specific diagnosis, treatment plan, and what to expect during and after treatment. Regular follow-up appointments and a strong support system are vital parts of managing life with breast cancer.

Summary

HER2 negative breast cancer refers to tumors that do not overexpress the HER2 protein. This status is determined through biopsy tests like IHC and FISH/CISH and is a critical factor in deciding the most effective treatment strategy. Unlike HER2 positive cancers, HER2 negative tumors do not respond to anti-HER2 targeted therapies. Treatment for HER2 negative breast cancer typically involves surgery, radiation, chemotherapy, and potentially hormone therapy if the tumor is also hormone receptor positive. Triple-negative breast cancer is an important subtype of HER2 negative breast cancer with its own unique treatment considerations. Understanding your HER2 status empowers you and your medical team to make informed decisions for your care.